	US 12,202,797 B2
	Method for producing pyrrole compound
Takashi Ouchi, Osaka (JP); Giho Goh, Daejeon (KR); Sunmi Kim, Daejeon (KR); Jinsoon Choi, Daejeon (KR); and Hunsoo Park, Daejeon (KR)
Assigned to Takeda Pharmaceutical Company Limited, Osaka (JP)
Filed by Takeda Pharmaceutical Company Limited, Osaka (JP)
Filed on Apr. 10, 2023, as Appl. No. 18/132,677.
Application 18/132,677 is a division of application No. 17/350,013, filed on Jun. 17, 2021, granted, now 11,649,206.
Application 17/350,013 is a division of application No. 16/739,707, filed on Jan. 10, 2020, granted, now 11,066,362, issued on Jul. 20, 2021.
Application 16/739,707 is a division of application No. 15/739,877, granted, now 10,570,091, issued on Feb. 25, 2020, previously published as PCT/JP2016/069258, filed on Jun. 29, 2016.
Claims priority of application No. 2015-131610 (JP), filed on Jun. 30, 2015.
Prior Publication US 2023/0322669 A1, Oct. 12, 2023
Int. Cl. C07D 207/36 (2006.01); B01J 8/02 (2006.01); B01J 21/04 (2006.01); B01J 23/44 (2006.01); B01J 29/08 (2006.01); C07B 31/00 (2006.01); C07B 41/06 (2006.01); C07B 61/00 (2006.01); C07C 253/30 (2006.01); C07C 255/28 (2006.01); C07C 255/42 (2006.01); C07D 207/34 (2006.01); C07D 401/12 (2006.01)

CPC C07D 207/36 (2013.01) [B01J 8/0278 (2013.01); B01J 21/04 (2013.01); B01J 23/44 (2013.01); B01J 29/08 (2013.01); C07B 31/00 (2013.01); C07B 41/06 (2013.01); C07B 61/00 (2013.01); C07C 253/30 (2013.01); C07C 255/28 (2013.01); C07C 255/42 (2013.01); C07D 207/34 (2013.01); C07D 401/12 (2013.01); B01J 2523/67 (2013.01); B01J 2523/68 (2013.01); B01J 2523/69 (2013.01); B01J 2523/824 (2013.01); B01J 2523/828 (2013.01); B01J 2523/847 (2013.01)]

17 Claims

1. A method for producing a compound represented by the formula

wherein R¹is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, and R²is a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, a chlorine atom or a fluorine atom, or a salt thereof, comprising subjecting a compound represented by the formula

wherein each symbol is as defined above, or a salt thereof to a reduction reaction, and then to hydrolysis, wherein the reduction reaction is a continuous hydrogenation in a fixed bed reactor filled with a supported metal catalyst.